Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

Development of an acuity scoring system to proactively address drug shortages and increase supply chain resiliency.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

ASHP and ASHP Foundation Pharmacy Forecast 2026: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025

Same author

Key partner priorities for measures of safe outpatient paediatric medication use.

BMJ quality & safety·2025

Same author

The Extent and Magnitude of Bias in Case-Crossover Studies of Real-World Non-transient Medications Patterns: A Simulation Study with Real-World Examples.

Drug safety·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Projecting future drug expenditures: 2011.

Fred Doloresco¹, Cory Fominaya, Glen T Schumock

¹Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|May 7, 2011

Summary

Drug spending moderated due to generics and economic factors, with specialized medications seeing cost increases. Projections for 2011 indicate continued growth in outpatient and clinic settings, with slower growth in hospitals.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: Jun 2, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Health Economics
Pharmaceutical Policy

Background:

Drug expenditures are influenced by various market and policy factors.
Recent trends show moderation in growth for widely used drugs and increases for specialized medications.

Purpose of the Study:

To discuss drug expenditure trends in 2009-2010.
To project drug expenditures for 2011.
To identify factors influencing future drug spending.

Main Methods:

Analysis of historical drug expenditure data (2008-2009).
Review of factors impacting drug spending, including generics, health care reform, and biosimilars.
Projection of drug expenditure growth for 2011 across different care settings.

Main Results:

Total U.S. drug expenditures rose 5.2% from 2008 to 2009.
Outpatient and clinic drug expenditures showed moderate to significant growth.
Hospital drug expenditures exhibited slower growth, with a 0.8% increase in early 2010.

Conclusions:

Projected 2011 drug expenditure increases: 3-5% (outpatient), 4-6% (clinic-administered), 1-3% (hospital).
Generic drugs and economic conditions are key drivers of moderated spending growth.
Health care reform and biosimilars are emerging trends with potential future impact.